Corcept Therapeutics Incorporated
https://www.corcept.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Corcept Therapeutics Incorporated
Corcept’s Coup De GRACE
The follow-on Cushing’s product relacorilant has hit in Phase III, and is forecast to lead the market – eventually.
Ambitious AAX Wants To Be Key Player In Next-Generation Antibodies
Emerging Company Profile: The Swedish biotech’s CEO Maria Lisa Knudsen believes that the firm’s two technologies make it an attractive prospective partner for big pharma.
Scrip Podcast: Biopharma’s Must-Know Early 2024 Catalysts
Crunch time is coming for a handful of companies expecting hugely consequential clinical readouts by the end of Q1 2024.
Biopharma’s Must-Know Q4 Catalysts
Cytokinetics has a lot riding on the upcoming Phase III readout for aficamten, and crunch time is coming for plenty of other groups, too.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Corcept Therapeutics Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice